SHENZHEN, China, CAMBRIDGE, Mass. and SHERMAN OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- BGI Genomics, a global leader in Next Generation Sequencing Services, and Sanguine BioSciences, Inc., a builder of data-integrated patient communities, have joined forces to develop a database of combined genomic and clinical
Timothy J. Triche MD, PhD, Chairman of Sanguine's Board of Directors, said in a statement: "Selecting the right patient cohort(s), and then recruiting swiftly are the ingredients of a successful clinical trial. The healthcare community has seen time and time again that selecting the wrong patient cohort(s) is a death sentence for the trial. Today, there is no other company that enables specific individual requests based on both Whole Genome & EMR data, and then works directly with those identified patients to enroll them into the trial. Together, Sanguine and BGI are making this a reality today, initially in Rheumatoid Arthritis."
"BGI has been a credible partner to the biopharma industry, providing quality NGS services and a diverse menu of biomarker assays," said Charles Bao, Ph.D., General Manager of BGI Americas, a subsidiary of BGI Genomics. "The partnership with Sanguine will allow precise and efficient clinical trial enrollment, and will enhance BGI's overall solution to its biopharma partners. Whole genome sequencing provides the most comprehensive and unbiased genomic profiling that will maximize the value of Sanguine's patient database. The sequencing will be performed on our own BGISEQ NGS platform, marking the first time this high quality, low cost solution is used in a large-scale profiling project in the biopharma space."
Sanguine is accelerating Precision Medicine by partnering with data-integrated patient communities. The Company has developed a disruptive, scalable Direct-to-Patient data collection and commercialization platform currently used by 20 out of the top 40 pharmaceutical companies and currently >15,000 patients.
About BGI Genomics
BGI Genomics is the division of BGI Group that provides a diverse menu of next generation sequencing and clinical testing services to support academic research, drug development and diagnostics. The company operates service laboratories under global quality standards in the US, Denmark, Hong Kong and mainland China. BGI Genomics leverages its sophisticated genomic research experience and massive sequencing capacity to assist customers with fast turnaround, delivering high quality data at affordable prices. More information is available at www.bgi.com
Sanguine BioSciences, Inc.Lindsey BurtonPhone: (818) 606-0513Email: email@example.com Website: www.sanguinebio.com
BGI GenomicsLouis SintasathPhone: (858) 344-8398Email: firstname.lastname@example.org Website: www.bgi.com
View original content:http://www.prnewswire.com/news-releases/bgi--sanguine-join-forces-to-increase-speed-and-efficiency-of-precision-clinical-trial-recruitment-300568131.html
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All